Study Details

A dose escalation and expansion study of ASP4132 to subjects with advanced refractory tumors and lymphoma

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02383368

Astellas Study ID

The unique identification code given by the study sponsor.

4132-CL-0001

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Condition

Lymphoma, Advanced/Metastatic Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Mar 2015 - Apr 2018

Masking

None (Open Label)

Enrollment number

39

An Open-Label, Dose-Escalation/Expansion Phase 1 Study of ASP4132 Given Orally to Patients with Advanced Refractory Solid Tumors and Lymphoma

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A dose escalation and expansion study of ASP4132 to subjects with advanced refractory tumors and lymphoma? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US10005

Fairfax, United States, 22031

Site US10007

Scottsdale, United States, 85259

Site US10001

New Haven, United States, 06520

Site US10004

Chicago, United States, 60637

Site US10002

Rochester, United States, 55905

Site US10003

Houston, United States, 77030